Find information on thousands of medical conditions and prescription drugs.

Digoxin

Digoxin is a cardiac glycoside extracted from the foxglove plant, digitalis. It is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and congestive heart failure that cannot be controlled by other medication. more...

Home
Diseases
Medicines
A
B
C
D
Dacarbazine
Dactinomycin
Dalmane
Danazol
Dantrolene
Dapoxetine
Dapsone
Daptomycin
Daraprim
Darvocet
Darvon
Daunorubicin
Daunorubicin
Daypro
DDAVP
Deca-Durabolin
Deferoxamine
Delsym
Demeclocycline
Demeclocycline
Demerol
Demulen
Denatonium
Depakene
Depakote
Depo-Provera
Desferal
Desflurane
Desipramine
Desmopressin
Desogen
Desogestrel
Desonide
Desoxyn
Desyrel
Detrol
Dexacort
Dexamethasone
Dexamfetamine
Dexedrine
Dexpanthenol
Dextran
Dextromethorphan
Dextromoramide
Dextropropoxyphene
Dextrorphan
Diabeta
Diacerein
Diacetolol
Dial
Diamox
Diazepam
Diazoxide
Dibenzepin
Diclofenac
Diclohexal
Didanosine
Dieldrin
Diethylcarbamazine
Diethylstilbestrol
Diethyltoluamide
Differin
Diflucan
Diflunisal
Digitoxin
Digoxin
Dihydrocodeine
Dihydroergotamine
Dihydrotachysterol
Dilantin
Dilaudid
Diltahexal
Diltiazem
Dimenhydrinate
Dimercaprol
Dimetapp
Dimethyl sulfoxide
Dimethyltryptamine
Dimetridazole
Diminazene
Diovan
Dioxybenzone
Diphenhydramine
Diphenoxylate
Dipipanone
Dipivefrine
Diprivan
Diprolene
Diproteverine
Dipyridamole
Disulfiram
Disulfiram
Dizocilpine
Dobutamine
Docetaxel
Docusate sodium
Dofetilide
Dolasetron
Dolobid
Dolophine
Domperidone
Donepezil
Dopamine
Dopram
Doral
Doramectin
Doriden
Dornase alfa
Doryx
Dostinex
Doxapram
Doxazosin
Doxepin
Doxil
Doxil
Doxorubicin
Doxy
Doxycycline
Doxyhexal
Doxylamine
Drisdol
Drixoral
Dronabinol
Droperidol
Drospirenone
Duloxetine
Durabolin
Duragesic
Duraphyl
Duraquin
Dutasteride
Dv
Dyclonine
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Actions

The main effects of digoxin are on the heart, its extracardiac effects are responsible for most of the side effects, i.e. nausea, vomiting, diarrhea and confusion.

Its main cardiac effects are:

  • A decrease of conduction of electrical impulses through the AV node, making it a commonly used drug in controlling the heart rate during atrial fibrillation or atrial flutter.
  • An increase of force of contraction via inhibition of the Na+/K+ ATPase pump (see below).

Mechanism of action

Digoxin binds to a site on the extracellular aspect of the α-subunit of the Na+/K+ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na+/K+ pump leads to increased Na+ levels, which in turn slows down the extrusion of Ca2+ via the Na+/Ca2+ exchange pump. Increased amounts of Ca2+ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by digoxin. This is a different mechanism from that of catecholamines.

Digoxin also increases vagal activity via its central action on the central nervous system, thus decreasing the conduction of electrical impulses through the AV node. This is important for its clinical use in different arrhythmias (see below).

Clinical use

Today, the most common indications for digoxin are probably atrial fibrillation and atrial flutter with rapid ventricular response. High ventricular rate leads to insufficient diastolic filling time. By slowing down the conduction in the AV node and increasing its refractory period, digoxin can reduce the ventricular rate. The arrhythmia itself is not affected, but the pumping function of the heart improves owing to improved filling.

The use of digoxin in congestive heart failure during sinus rhythm is controversial. In theory the increased force of contraction should lead to improved pumping function of the heart, but its effect on prognosis is disputable and digoxin is no longer the first choice for congestive heart failure. However, it can still be useful in patients who remain symptomatic despite proper diuretic and ACE inhibitor treatment.

Digoxin is usually given by mouth, but can also be given by IV injection in urgent situations (the IV injection should be slow, heart rhythm should be monitored). The half life is about 36 hours, digoxin is given once daily, usually in 125μg or 250μg dosing. In patients with decreased kidney function the half life is considerably longer, calling for a reduction in dosing or a switch to a different glycoside (digitoxin).

Read more at Wikipedia.org


[List your site here Free!]


Is digoxin harmful in women with heart failure? - Tips from Other Journals
From American Family Physician, 4/15/03 by Bill Zepf

In 1997, the Digitalis Investigation Group trial found that treatment with digoxin did not decrease overall mortality among patients with heart failure but did decrease the risk of hospitalization for worsening heart failure. Rathore and associates conducted a post hoc subgroup analysis of the study data focused on sex-based differences in the outcome effects of digoxin therapy.

The analysis assessed 6,800 patients from the Digitalis Investigation Group study. These patients were randomly assigned to receive either digoxin or placebo and were followed for three years. The majority of patients were white, and only 22 percent of patients were women. Most patients had New York Heart Association functional class II or class III heart failure and were receiving 0.25 mg of digoxin daily. Compared with the male subjects, female participants were slightly older, had a slightly better ejection fraction, and were less likely to have an ischemic primary cause of congestive heart failure.

The three-year mortality rate among men was not significantly different in patients receiving digoxin and in patients receiving placebo (35.2 versus 36.9 percent, respectively). However, women receiving digoxin had a slightly higher mortality rate than those receiving placebo (33.1 versus 28.9 percent, respectively); this difference was of borderline statistical significance. Rates of hospitalization were decreased in both sexes with the use of digoxin, but the effect was more profound in men (-8.9 percent) than in women (-4.2 percent).

The authors conclude that their findings of increased mortality and a smaller reduction in the rate of hospitalization in women "raise strong concern about the appropriate role of digoxin therapy in women."

EDITOR'S NOTE: Most clinical guidelines for heart failure advocate the use of digoxin; however, most practicing physicians are aware of the continuing clinical controversies surrounding this medication. The differences in cardiac disease between men and women have received a fair amount of press and medical attention in recent years. It is worth noting that the 95 percent confidence intervals for the mortality difference between digoxin and placebo in this study included zero for both men and women. Therefore, it is possible that the small differences in death rates for both sexes could be caused entirely by chance. While the media may trumpet the injurious effects of digoxin in women, physicians should be mindful of the statistical pitfalls in these reports.--B.Z.

COPYRIGHT 2003 American Academy of Family Physicians
COPYRIGHT 2003 Gale Group

Return to Digoxin
Home Contact Resources Exchange Links ebay